DT2216 was highly potent against various Bcl-xL-dependent leukemia and cancer cells because it effectively inhibited the growth of several xenograft tumors as a single agent (e.g., MOLT-4 T-ALL xenograft) or in combination with other therapeutic agents (e.g., H146 SCLC xenograft, MDA-MB231 breast cancer xenograft, and T-ALL PDX models) [13]. Here, BCL2L1 is linked to cancer.